Lidoryx 5%
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Lidoryx 5%
- Generic name
- LIDOCAINE HCL
- Manufacturer
- Oncora Pharma, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 38e82d76-2983-49cd-9248-95fbd0eec299
- SPL ID
- d98380a1-ce01-4b8c-ab5c-bb0f51ce4913
- Version
- 1
- Effective date
- 2026-10-22
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:35:49
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Lidoryx 5% | openfda.brand_name | |
| generic name | LIDOCAINE HCL | openfda.generic_name | |
| manufacturer name | Oncora Pharma, LLC | openfda.manufacturer_name | |
| ndc | package | 85477-731-07 | openfda.package_ndc |
| ndc | product | 85477-731 | openfda.product_ndc |
| ndc11 | package | 85477073107 | derived:openfda.package_ndc |
| rxcui | 1010057 | openfda.rxcui | |
| spl id | d98380a1-ce01-4b8c-ab5c-bb0f51ce4913 | id | |
| spl set id | 38e82d76-2983-49cd-9248-95fbd0eec299 | set_id | |
| unii | V13007Z41A | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS: For external use only. Not for ophthalmic use.
warnings and cautions
PRECAUTIONS: If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. Lidoryx 5% should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of lidocaine.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: During or immediately after treatment, the skin at the site of treatment may develop erythema or edema or may be the locus of abnormal sensation.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.